Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL
Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate
XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study
Study Suggests Biomarker For Resistance to Tamoxifen
Radiation, Tamoxifen After Surgery Reduce Breast Cancer Occurrence
Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint
Patients Who Smoke In Treatment Do Worse Than Those Who Quit
Dendritic Cell Vaccine May Boost Median Survival
Decline In Breast Cancer May Be Related to Drop In HT
Triple-Negative Breast Cancer Increases With Number of Births
PSA Velocity Poor Predictor Of Prostate Cancer Occurrence
Statins Associated With Lower Risk Of High-Grade Prostate Cancer
Mentholated Cigarettes Cause No More Lung Cancer, Deaths
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves BMS’s Yervoy For Metastatic Melanoma
Trending Stories
- She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI - HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine - Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - An overlooked immune cell population may offer new direction for cell and gene therapy
- In The Headlines: What happens when you apply a tumor board model to financial toxicity?
